Full-Time

Account Executive

Merit Oncology

Posted on 9/23/2025

Merit Medical Systems

Merit Medical Systems

1,001-5,000 employees

Manufactures disposable medical devices for interventions

No salary listed

Company Does Not Provide H1B Sponsorship

Minneapolis, MN, USA

In Person

Category
Sales & Account Management (1)
Required Skills
Sales
Financial analysis
Requirements
  • Education and/or experience equivalent to a related Bachelors’ Degree.
  • A minimum of three years of direct sales experience, preferably in selling Oncology Capital Equipment.
  • Ability to communicate effectively with and to understand the needs of others in a sales relationship.
  • A high degree of personal motivation and drive to achieve personal and professional goals.
  • Excellent oral presentation skills and the ability to think quickly to apply facts in analyzing a problem and explaining that answer to a group of medical technicians and clinicians.
  • Ability to learn the usage of medical equipment and to identify and explain possible improvements in usage.
  • Ability to work effectively as a team member to achieve organization goals.
  • Ability to utilize business mathematics to figure percentages, prepare financial and sales information.
  • A high degree of personal organization skills, including the ability to record and report information and to document work performed.
  • Ability to work independently with a minimum of supervision.
  • Ability to travel extensively and work long hours to achieve goals, as required.
  • Excellent driving record with no driving accidents in the past three years or no more than one driving ticket in the last three years.
  • Demonstrated computer skills preferably spreadsheets, word processing, database and other applicable software programs.
Responsibilities
  • Presents and sells Merit products to new and existing accounts and follows up with these customers to confirm that products delivered meet their needs.
  • Makes in-service presentations to clinicians, explaining new products and their use.
  • Maintains close relationships with clients to ensure that their needs are understood and met.
  • Coordinates with Merit marketing and sales staff to ensure that products are delivered on time, to stay informed about new products, and to provide customer feedback about product innovation.
  • Identifies potential customers and introduces them to the products offered by Merit.
  • Prepares customized drawings for clients needing custom kits or manifolds.
  • Prepares and submits pricing contracts to clients for products.
  • Follows up with clients to identify opportunities to increase sales volume and profitability.
  • Resolves problems with clients regarding manufacturing or delivery problems, if they occur.
  • Prepares a monthly report summarizing monthly sales results achieved, contacts made, needs for change in products and suggestions for improvement in Merit's procedures.
  • Participates in a variety of sales training and planning meetings to learn about new products and marketing promotions, and to share information about sales goals.
  • Maintains a high level of knowledge about Merit and competitor products and their advantages and disadvantages.
  • Sets and achieves personal performance goals for sales volume, new contacts made, new client sales and other related sales results achieved.
  • Participates as a member of the Merit sales team to improve Merit's ability to increase market share by identifying ways to increase product quality and customer satisfaction.
  • Travels by car, airplane, bus, etc. to perform sales duties with clients.
  • Performs other sales related duties, as required.
Desired Qualifications
  • Experience in selling Oncology Capital Equipment.
Merit Medical Systems

Merit Medical Systems

View

Merit Medical Systems develops, manufactures, and distributes proprietary disposable medical devices used in interventional, diagnostic, and therapeutic procedures across cardiology, radiology, oncology, critical care, and endoscopy. These one-time-use devices are used during procedures and supported by a global sales force and clinical team that provides training and support to hospitals. The company differentiates itself with a broad, multi-specialty product portfolio, an international footprint for manufacturing and distribution, and strong customer service and clinical support. Its goal is to transform patient care by delivering medical solutions that meet hospitals’ and patients’ needs worldwide.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

South Jordan, Utah

Founded

1987

Simplify Jobs

Simplify's Take

What believers are saying

  • Therapeutic category grew 10% to $126.4M in Q1 2026 from endoscopy and cardiac.
  • View Point projects $14-16M revenue in 2027 with 20% annual OneMark growth.
  • Non-GAAP operating margin hit record 19.7% despite tariff headwinds in Q1 2026.

What critics are saying

  • OEM segment fell 14% in Q1 2026 from Asia-Pacific weakness and US destocking.
  • Tariffs cost $4.6M in Q1 with $15M annual impact compressing margins.
  • Delayed WRAPSODY CIE reimbursement blocks peripheral intervention revenue ramp.

What makes Merit Medical Systems unique

  • View Point Medical acquisition triples oncology market via OneMark ultrasound system.
  • Resilience esophageal stent offers superior anti-migration flanges and unique 14-20mm sizes.
  • Reorganized portfolio into Foundational and Therapeutic categories reflects clinical applications.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Paid Vacation

Paid Sick Leave

Paid Holidays

401(k) Retirement Plan

Health Savings Account/Flexible Spending Account

Flexible Work Hours

Company News

The Associated Press
Apr 1st, 2026
Merit Medical acquires View Point Medical for $140M to expand breast cancer detection portfolio

Merit Medical Systems has acquired View Point Medical for approximately $140 million, expanding its therapeutic oncology portfolio. The California-based company manufactures the OneMark Detection Imaging System and tissue markers for breast and soft tissue tumour localisation. Merit paid $90 million in cash at closing, with two deferred payments of $25 million each scheduled over the next two years. The acquisition targets an estimated 1.3 million biopsy procedures annually in the United States. View Point's ultrasound-enhanced technology will complement Merit's existing SCOUT platform, offering physicians more localisation options during diagnostic biopsies and potentially reducing the need for separate pre-surgery procedures. For 2026, the acquisition is projected to contribute $2 million to $4 million in revenue. Merit expects revenue of $14 million to $16 million in 2027, with OneMark sales growing at least 20% annually.

PR Newswire
Mar 24th, 2026
Medtronic expands pain portfolio with FDA-cleared ViaVerte basivertebral nerve ablation system

Medtronic has entered into a distribution agreement with Merit Medical Systems to offer the ViaVerte system, an FDA-cleared basivertebral nerve ablation treatment for chronic vertebrogenic lower back pain. The minimally invasive, implant-free system features a physician-controlled steerable mechanism for precise nerve targeting. ViaVerte, which will be available later this year, offers same-day outpatient procedures for patients suffering from chronic lower back pain caused by damaged vertebral endplates. According to the American Chronic Pain Association, one in three Americans suffer from chronic pain. The agreement expands Medtronic's pain interventions portfolio, which includes spinal cord stimulation, vertebral augmentation and targeted drug delivery. Merit Medical currently supplies Medtronic with inflation syringes and steerable balloon catheters for vertebral compression fracture treatments.

Yahoo Finance
Mar 16th, 2026
Merit Medical launches Resilience esophageal stent with anti-migration design for cancer treatment

Merit Medical Systems has launched the Resilience Through-the-Scope Esophageal Stent in the US, designed to treat esophageal fistulas and strictures caused by malignant tumours. The stent features proprietary anti-migration flanges to prevent movement and is designed to demonstrate the greatest migration resistance amongst currently available TTS stents. A single-handed deployment system enables precise placement, whilst unique sizing options — 14mm x 50mm, 17mm x 50mm, and 20mm x 50mm — address various clinical needs unavailable elsewhere. Esophageal cancer is the sixth most common cause of cancer deaths globally. The new stent joins Merit's endoscopy portfolio, offering physicians enhanced control for treating patients experiencing difficulty swallowing, regurgitation and chest pain caused by esophageal narrowing.

Yahoo Finance
Mar 16th, 2026
Wells Fargo downgrade triggers institutional selling in Merit Medical Systems despite $1.61B revenue guidance

Merit Medical Systems has faced pressure following a Wells Fargo downgrade and subsequent institutional selling, creating a disconnect between market sentiment and the company's fundamentals. The medical device supplier maintains solid operations despite the negative mood shift. Merit recently issued 2026 revenue guidance of $1.610 billion to $1.630 billion, implying mid-single-digit growth despite current headwinds including delayed WRAPSODY CIE reimbursement and higher operating expenses. The company's narrative projects $1.8 billion revenue and $197.2 million earnings by 2028, requiring 7% annual revenue growth. Key risks include continued weakness in China and volume-based purchasing pressure. Simply Wall St Community members currently value the stock between $82.26 and $103.55, suggesting potential upside of up to 48% from current levels.

Yahoo Finance
Feb 26th, 2026
Merit Medical Q4 earnings beat estimates as revenues rise 11% to $394M

Merit Medical Systems reported fourth-quarter 2025 adjusted earnings per share of $1.04, up 12% year over year and beating the Zacks Consensus Estimate by 8.3%. GAAP EPS was 63 cents, up 37% year over year. Fourth-quarter revenues reached $393.9 million, up 11% on a reported basis and topping the consensus estimate by 0.8%. At constant exchange rate, revenues increased 10%, with organic growth of 6.8%. For the full year, adjusted EPS improved 11% to $3.83, whilst total revenues rose 12% to $1.52 billion on a reported basis. US sales grew 11.6% to $238.2 million, and international sales increased 9.9% to $155.7 million. The Cardiovascular segment, which accounts for the majority of revenue, grew 11% to $373.9 million.

INACTIVE